Do you want to read an article? Please log in or register.
Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Variation in lung function and nutritional decline in cystic fibrosis by genotype: An analysis of the Canadian cystic fibrosis registry
J Cyst Fibros.
Leung GJ, Cho TJ, Kovesi T, Hamid JS, Radhakrishnan D
doi: 10.1016/j.jcf.2019.06.007.
RECOMMENDED
Pulmonary Fibrosis
Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens: A Cohort Study Using National Registry Data
Ann Am Thorac Soc.
Frost FJ, Nazareth DS, Charman SC, Winstanley C, Walshaw MJ
doi: 10.1513/AnnalsATS.201902-122OC.
RECOMMENDED
Pulmonary Fibrosis
Survival and lung transplant outcomes for individuals with advanced cystic fibrosis lung disease in the United States and Canada: an analysis of national registries
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Chest
Ramos KJ, Sykes J, Stanojevic S, Ma X, Ostrenga JS, Fink A, Quon BS, Marshall BC, Faro A, Petren K, Elbert A, Goss CH, Stephenson AL
doi: 10.1016/j.chest.2021.04.010
RECOMMENDED
Pulmonary Fibrosis
Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Campredon A, Battistella E, Martin C, Durieu I, Mely L, Marguet C, Belleguic C, Murris-Espin M, Chiron R, Fanton A, Bui S, Reynaud-Gaubert M, Reix P, Hoang-Thi TN, Vakalopoulou M, Revel MP, Da Silva J, Burgel PR, Chassagnon G, French Cystic Fibrosis Reference Network Study Group.
doi: 10.1183/13993003.01344-2021
RECOMMENDED
Pulmonary Fibrosis
Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
Reix P, Tatopoulos A, Ioan I, Le Bourgeois M, Bui S, Choukroun ML, Bessaci-Kabouya K, Gerardin M, Bokov P, Da Silva J, Paillasseur JL, Burgel PR, French Cystic Fibrosis Reference Network study group.
doi: 10.1016/j.jcf.2021.06.002
RECOMMENDED
Further Publications
Clinical characteristics associated with lung function decline in individuals with adult-diagnosed cystic fibrosis: Contemporary analysis of the Canadian CF Registry
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest
Desai S, Stanojevic S, Lam GY, Stephenson AL, Quon BS
doi: 10.1016/j.chest.2021.02.015
RECOMMENDED
Pulmonary Fibrosis
Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry Cohort study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J
McKone EF, Ariti C, Jackson A, Zolin A, Carr SB, Orenti A, van Rens J, Lemonnier L, Macek M Jr, Keogh RH, Naehrlich L, European Cystic Fibrosis Society Patient Registry.
doi: 10.1183/13993003.02288-2020
RECOMMENDED
Lung Cancer
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M
doi: 10.1016/j.lungcan.2021.04.022
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial
Lancet Respir Med.
Ratjen F, Hug C, Marigowda G, Tian S, Huang X, Stanojevic S, Milla CE, Robinson PD, Waltz D, Davies JC; VX14-809-109 investigator group
doi: 10.1016/